Skip to main content
. 2018 Dec 4;104(5):955–962. doi: 10.3324/haematol.2018.206797

Figure 3.

Figure 3.

Probabilities of molecular relapse-free survival after dose reduction to imatinib at 400 mg/day. At 12 and 36 months, horizontal crossbars indicate the upper and lower limit of the 95% confidence interval (CI) for the estimated probability.